The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
25922884 |
5 |
Top-down Targeted Metabolomics Reveals a Sulfur-Containing Metabolite with Inhibitory Activity against Angiotensin-Converting Enzyme in Asparagus officinalis. |
Riken Center For Sustainable Resource Science |
25016232 |
109 |
CoMFA and CoMSIA analysis of ACE-inhibitory, antimicrobial and bitter-tasting peptides. |
Tianjin University |
24900839 |
24 |
Interkingdom pharmacology of Angiotensin-I converting enzyme inhibitor phosphonates produced by actinomycetes. |
Vanderbilt University Department Of Chemistry |
24735644 |
19 |
Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-ß hydrolysis. |
University Of Lille |
23061607 |
10 |
Organosilicon molecules with medicinal applications. |
University Of California Davis |
3379417 |
5 |
Chemical and pharmaceutical studies on medicinal plants in Paraguay. Geraniin, an angiotensin-converting enzyme inhibitor from "paraparai mi," Phyllanthus niruri. |
TBA |
18078750 |
76 |
Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite. |
Glaxosmithkline |
9379435 |
30 |
Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data. |
University Of Michigan |
7629809 |
140 |
Amino acid side chain descriptors for quantitative structure-activity relationship studies of peptide analogues. |
University Of Illinois At Chicago |
8360884 |
134 |
Three-dimensional quantitative structure-activity relationship of angiotesin-converting enzyme and thermolysin inhibitors. II. A comparison of CoMFA models incorporating molecular orbital fields and desolvation free energies based on active-analog and complementary-receptor-field alignment rules. |
Washington University |
| 20 |
Dual metalloprotease inhibitors. III. utilization of bicyclic and monocyclic diazepinone based mercaptoacetyls |
TBA |
| 26 |
Dual metalloprotease inhibitors. II. Effect of substitution and stereochemistry on benzazepinone based mercaptoacetyls |
TBA |
| 30 |
Dual metalloprotease inhibitors. I. constrained peptidomimetics of mercaptoacyl dipeptides |
TBA |
21413808 |
170 |
Synopsis of some recent tactical application of bioisosteres in drug design. |
Bristol-Myers Squibb Pharmaceutical Research And Development |
21381769 |
56 |
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. |
Universite£ |
22882079 |
26 |
Synthesis and evaluation of silanediols as highly selective uncompetitive inhibitors of human neutrophil elastase. |
Aarhus University |
21780776 |
40 |
Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry. |
Wroclaw University Of Technology |
19715320 |
87 |
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. |
University Of Florida |
19596577 |
26 |
Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors. |
Dipartimento Di Chimica |
18160283 |
26 |
Targeting ACE and ECE with dual acting inhibitors. |
Universit£ |
16220969 |
219 |
Designed multiple ligands. An emerging drug discovery paradigm. |
Organon Laboratories |
15658862 |
30 |
Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. |
University Institute Of Pathology |
12852763 |
20 |
Computer-aided selection of potential antihypertensive compounds with dual mechanism of action. |
Institute Of Biomedical Chemistry Of Russian Academy Of Medical Sciences |
12477342 |
27 |
2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery. |
Merck Research Laboratories |
10669559 |
180 |
Protease inhibitors: current status and future prospects. |
University Of Queensland |
10882358 |
62 |
Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. |
F. Hoffmann-La Roche |
10508425 |
68 |
Mixture-based synthetic combinatorial libraries. |
Torrey Pines Institute For Molecular Studies |
8021926 |
41 |
New thiol inhibitors of neutral endopeptidase EC 3.4.24.11: synthesis and enzyme active-site recognition. |
University Of Paris |
8340909 |
14 |
Excursions in drug discovery. |
Merck Research Laboratories |
1995872 |
5 |
Molecular and crystal structures of MDL27,467A hydrochloride and quinapril hydrochloride, two ester derivatives of potent angiotensin converting enzyme inhibitors. |
University Of Calgary |
2160536 |
13 |
Angiotensin converting enzyme inhibitors. 10. Aryl sulfonamide substituted N-[1-carboxy-3-phenylpropyl]-L-alanyl-L-proline derivatives as novel antihypertensives. |
Rorer Central Research |
2544729 |
8 |
Angiotensin converting enzyme inhibitors: spirapril and related compounds. |
Schering-Plough |
2566685 |
47 |
Inhibition of aminopeptidases by peptides containing ketomethylene and hydroxyethylene amide bond replacements. |
University Of Wisconsin-Madison |
2913292 |
23 |
Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives. |
Tanabe Seiyaku |
3005569 |
17 |
Conformationally restricted inhibitors of angiotensin converting enzyme: synthesis and computations. |
TBA |
3020249 |
29 |
Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types. |
TBA |
2993618 |
19 |
Synthesis and biological activity of modified peptide inhibitors of angiotensin-converting enzyme. |
TBA |
2983076 |
2 |
Conformational analysis and active site modelling of angiotensin-converting enzyme inhibitors. |
TBA |
2999394 |
21 |
Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives. |
TBA |
6173481 |
24 |
Novel synthesis of (S)-1-[5-(benzoylamino)-1,4-dioxo-6-phenylhexyl]-L-proline and analogues: potent angiotensin converting enzyme inhibitors. |
TBA |
6259352 |
8 |
Synthesis and angiotensin-converting enzyme inhibitory activity of 3-(Mercaptomethyl)-2-oxo-1-pyrrolidineacetic acids and 3-(Mercaptomethyl)-2-oxo-1-piperidineacetic acids. |
TBA |
| 66 |
Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme by N-phosphonomethyl and N-carboxyalkyl dipeptides |
TBA |
| 20 |
4-Substituted proline derivatives that inhibit angiotensin converting enzyme and neutral endopeptidase 24.11. |
TBA |
| 11 |
Thiol and hydroxamic acid containing inhibitors of endothelin converting enzyme |
TBA |
19949058 |
15 |
Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist. |
Glaxosmithkline |
19899765 |
69 |
Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. |
Cea |
19703773 |
63 |
The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. |
Gsk Medicines Research Centre |
1517742 |
9 |
Inhibition of Angiotensin-I-Converting Enzyme by Tetrahydroxyxanthones Isolated from Tripterospermum lanceolatum |
TBA |
| 23 |
Novel low molecular renin inhibitors which show good oral blood pressure lowering effects in marmosets |
TBA |
| 27 |
Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by tricyclic benzazepinone thiols |
TBA |
| 28 |
α-Mercaptoacyl dipeptides that inhibit angiotensin converting enzyme and neutral endopeptidase 24.11 |
TBA |
| 5 |
Peptide mimics of glycylproline as inhibitors of prolidase |
TBA |
| 7 |
The design of a dipeptide library for screening at peptide receptor sites |
TBA |
| 2 |
Synthesis of 6-amino-5-oxo-7-phenyl-1,4-oxazepines as conformationally constrained gauche (−) dipeptide mimetics |
TBA |
| 1 |
An acyliminium ion route to Cis and Trans "Anti" phe-gly dipeptide mimetics |
TBA |
19042128 |
76 |
Synthesis and biological evaluation of N-mercaptoacylcysteine derivatives as leukotriene A4 hydrolase inhibitors. |
Santen Pharmaceutical |
18790648 |
317 |
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. |
University Of Athens |
18701300 |
55 |
Synthesis and elastase-inhibiting activity of 2-pyridinyl-isothiazol-3(2H)-one 1,1-dioxides. |
University Of Leipzig |
18674901 |
32 |
Synthesis and biological evaluation of N-mercaptoacylproline and N-mercaptoacylthiazolidine-4-carboxylic acid derivatives as leukotriene A4 hydrolase inhibitors. |
Santen Pharmaceutical |
16784850 |
14 |
Synthesis of novel keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors. |
University Of Cape Town |
16784843 |
4 |
Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme. |
University Of Cape Town |
16464585 |
4 |
Structure-activity relationship study between Ornithyl-Proline and Lysyl-Proline based tripeptidomimics as angiotensin-converting enzyme inhibitors. |
Institute Of Genomics And Integrative Biology |
11551755 |
18 |
Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor. |
British Biotech Pharmaceuticals |
11384231 |
26 |
2-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)- and 2-(2,2-dioxo-1,4-dihydro-2H-2lambda6-benzo[1,2,6]thiadiazin-3-yl)-N-hydroxy-acetamides as potent and selective peptide deformylase inhibitors. |
F. Hoffmann-La Roche |
9484512 |
130 |
Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. |
Shionogi |
9046341 |
44 |
Meta-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors. |
Ciba-Geigy |
8421293 |
32 |
Exploration of neutral endopeptidase active site by a series of new thiol-containing inhibitors. |
University Of Paris |
8057292 |
83 |
Mercaptoacyl amino acid inhibitors of atriopeptidase. 1. Structure-activity relationship studies of methionine and S-alkylcysteine derivatives. |
Schering-Plough Research Institute |
7966160 |
7 |
PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores. |
Proteus Molecular Design |
6288947 |
6 |
Angiotensin converting enzyme inhibitors: modifications of a tripeptide analogue. |
TBA |
28442252 |
62 |
Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome. |
Ranbaxy Laboratories |
1331459 |
1 |
The first mechanism-based inactivators for angiotensin-converting enzyme. |
Baxter Diagnostics |